Department of Internal Medicine, Piedmont Athens Regional, Athens, GA, USA.
Division of Rheumatology, Loma Linda University Health, Loma Linda, USA.
Clin Rheumatol. 2023 Oct;42(10):2833-2839. doi: 10.1007/s10067-023-06690-w. Epub 2023 Jul 5.
There is a scarcity of national population-based studies on polymyositis (PM)/dermatomyositis (DM) readmissions in the USA. In this study, we aim to describe the rates, reasons for readmissions, and characteristics of readmissions for adults hospitalized for PM/DM in the USA.
We analyzed the 2018 Nationwide Readmissions Database (NRD). We included index hospitalizations for all adult DM/PM patients with a principal diagnosis of PM/DM using ICD-10 codes. We excluded elective and traumatic readmissions. Using a "rank" command in STATA, the most common specific principal diagnosis of readmissions was outlined. Chi-square tests were used to compare baseline characteristics between readmissions and index hospitalizations. STATA 16 was used for analysis.
A total of 1610, 1286, and 842 index hospitalizations with a principal diagnosis of PM/DM, that were discharged alive, were included in the 30-, 90-, and 180-day readmission analysis, respectively. Among these, 193 (12%), 276 (21.5%), and 240 (28.5%) were readmitted within 30, 90, and 180 days, respectively. PM and sepsis were the most common reasons for reasons across the 3 timeframes. 30-day readmissions were responsible for an aggregate of 4.1 million US dollars in total hospital cost and 1518 hospital days in 2018. Compared to index hospitalizations, 30-day readmissions have higher Charlson Comorbidity Index scores, severe-extreme loss of function, obesity, and deep venous thrombosis.
About a third of PM/DM hospitalized patients are readmitted within 180 days. Readmissions constitute a significant economic burden to the health care system. PM and sepsis are the main reasons for readmissions. Key points • About a third of polymyositis (PM)/dermatomyositis (DM) hospitalized patients are readmitted within 180 days • PM and sepsis are the main reasons for readmissions. • Readmissions of PM/DM Patients constitute a significant economic burden to the health care system. • Compared to index hospitalizations, 30-day readmissions have higher Charlson comorbidity index scores, severe-extreme loss of function, obesity, and deep venous thrombosis.
美国缺乏全国性的基于人群的多发性肌炎(PM)/皮肌炎(DM)再入院研究。本研究旨在描述美国因 PM/DM 住院的成年人的再入院率、再入院原因和再入院特征。
我们分析了 2018 年全国再入院数据库(NRD)。我们使用 ICD-10 代码纳入所有主要诊断为 PM/DM 的成年 DM/PM 患者的索引住院。我们排除了选择性和创伤性再入院。使用 STATA 中的“rank”命令,概述了最常见的特定再入院主要诊断。使用卡方检验比较再入院和索引住院的基线特征。使用 STATA16 进行分析。
共纳入 1610 例、1286 例和 842 例主要诊断为 PM/DM 的出院后存活的索引住院患者,分别进行 30 天、90 天和 180 天的再入院分析。其中,分别有 193 例(12%)、276 例(21.5%)和 240 例(28.5%)在 30 天、90 天和 180 天内再次入院。30 天内再入院的主要原因为 PM 和败血症。在这 3 个时间范围内,这是最常见的原因。2018 年,30 天再入院导致的总住院费用为 410 万美元,住院天数为 1518 天。与索引住院相比,30 天再入院的患者Charlson 合并症指数评分较高,严重/极度功能丧失,肥胖和深静脉血栓形成。
大约三分之一的 PM/DM 住院患者在 180 天内再次入院。再入院给医疗保健系统带来了重大的经济负担。PM 和败血症是再入院的主要原因。主要发现 • 大约三分之一的多发性肌炎(PM)/皮肌炎(DM)住院患者在 180 天内再次入院。 • PM 和败血症是再入院的主要原因。 • PM/DM 患者的再入院给医疗保健系统带来了重大的经济负担。 • 与索引住院相比,30 天再入院的患者 Charlson 合并症指数评分较高,严重/极度功能丧失,肥胖和深静脉血栓形成。